Estimation of absolute risk for prostate cancer using genetic markers and family history - PubMed (original) (raw)
. 2009 Oct 1;69(14):1565-72.
doi: 10.1002/pros.21002.
Jielin Sun, A Karim Kader, Sara Lindström, Fredrik Wiklund, Fang-Chi Hsu, Jan-Erik Johansson, S Lilly Zheng, Gilles Thomas, Richard B Hayes, Peter Kraft, David J Hunter, Stephen J Chanock, William B Isaacs, Henrik Grönberg
Affiliations
- PMID: 19562736
- PMCID: PMC2793526
- DOI: 10.1002/pros.21002
Estimation of absolute risk for prostate cancer using genetic markers and family history
Jianfeng Xu et al. Prostate. 2009.
Abstract
Background: Multiple DNA sequence variants in the form of single-nucleotide polymorphisms (SNPs) have been found to be reproducibly associated with prostate cancer (PCa) risk.
Methods: Absolute risk for PCa among men with various numbers of inherited risk alleles and family history of PCa was estimated in a population-based case-control study in Sweden (2,893 cases and 1,781 controls), and a nested case-control study from the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial in the U.S. (1,172 cases and 1,157 controls).
Results: Increased number of risk alleles and positive family history were independently associated with PCa risk. Considering men with 11 risk alleles (mode) and negative family history as having baseline risk, men who had >or=14 risk alleles and positive family history had an odds ratio (OR) of 4.92 [95% confidence interval (CI): 3.64-6.64] in the Swedish study. These associations were confirmed in the U.S. population. Once a man's SNP genotypes and family history are known, his absolute risk for PCa can be readily calculated and easily interpreted. For example, 55-year-old men with a family history and >or=14 risk alleles have a 52% and 41% risk of being diagnosed with PCa in the next 20 years in the Swedish and U.S. populations, respectively. In comparison, without knowledge of genotype and family history, these men had an average population absolute risk of 13%.
Conclusion: This risk prediction model may be used to identify men at considerably elevated PCa risk who may be selected for chemoprevention.
Conflict of interest statement
Conflict of interest statement
There is no potential conflict of interest relevant to this article.
Similar articles
- Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
Sun J, Kader AK, Hsu FC, Kim ST, Zhu Y, Turner AR, Jin T, Zhang Z, Adolfsson J, Wiklund F, Zheng SL, Isaacs WB, Grönberg H, Xu J. Sun J, et al. Prostate. 2011 Mar 1;71(4):421-30. doi: 10.1002/pros.21256. Epub 2010 Sep 28. Prostate. 2011. PMID: 20878950 Free PMC article. - Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA, Xu J, Chen H, Kader AK. Liss MA, et al. Prostate. 2015 Sep;75(12):1322-8. doi: 10.1002/pros.23012. Epub 2015 May 15. Prostate. 2015. PMID: 25982801 Clinical Trial. - Homeobox B13 G84E Mutation and Prostate Cancer Risk.
Nyberg T, Govindasami K, Leslie G, Dadaev T, Bancroft E, Ni Raghallaigh H, Brook MN, Hussain N, Keating D, Lee A, McMahon R, Morgan A, Mullen A, Osborne A, Rageevakumar R; UK Genetic Prostate Cancer Study Collaborators; Kote-Jarai Z, Eeles R, Antoniou AC. Nyberg T, et al. Eur Urol. 2019 May;75(5):834-845. doi: 10.1016/j.eururo.2018.11.015. Epub 2018 Dec 8. Eur Urol. 2019. PMID: 30527799 Free PMC article. - A comparison of genetic risk score with family history for estimating prostate cancer risk.
Helfand BT. Helfand BT. Asian J Androl. 2016 Jul-Aug;18(4):515-9. doi: 10.4103/1008-682X.177122. Asian J Androl. 2016. PMID: 27004541 Free PMC article. Review. - THADA gene polymorphism and prostate cancer risk: a meta-analysis.
Zhao F, Xu Y, Yang K, Liu M, Wei D, Zhang Y, Shi X, Yang F, Wang X, Liang S, Zhao C, Chen X, Sun L, Zhu X, Wang N, Hui J, Zhang Y, Zhu L, Yang Y, Tang L, Wang J, Yang Z. Zhao F, et al. Oncol Res Treat. 2014;37(3):106-10. doi: 10.1159/000360206. Epub 2014 Feb 21. Oncol Res Treat. 2014. PMID: 24685913 Review.
Cited by
- CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
Nyberg T, Brook MN, Ficorella L, Lee A, Dennis J, Yang X, Wilcox N, Dadaev T, Govindasami K, Lush M, Leslie G, Lophatananon A, Muir K, Bancroft E, Easton DF, Tischkowitz M, Kote-Jarai Z, Eeles R, Antoniou AC. Nyberg T, et al. J Clin Oncol. 2023 Feb 10;41(5):1092-1104. doi: 10.1200/JCO.22.01453. Epub 2022 Dec 9. J Clin Oncol. 2023. PMID: 36493335 Free PMC article. - Empirical evaluation of sub-cohort sampling designs for risk prediction modeling.
Lee M, Zeleniuch-Jacquotte A, Liu M. Lee M, et al. J Appl Stat. 2020 Dec 21;48(8):1374-1401. doi: 10.1080/02664763.2020.1861225. eCollection 2021. J Appl Stat. 2020. PMID: 35706464 Free PMC article. - Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk.
Bancroft EK, Raghallaigh HN, Page EC, Eeles RA. Bancroft EK, et al. Curr Genet Med Rep. 2021;9(4):47-58. doi: 10.1007/s40142-021-00202-5. Epub 2021 Oct 8. Curr Genet Med Rep. 2021. PMID: 34790437 Free PMC article. Review. - Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer.
Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. Wu C, et al. Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14. Cancer Commun (Lond). 2021. PMID: 34520132 Free PMC article. - Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics.
Allemailem KS, Almatroudi A, Alrumaihi F, Makki Almansour N, Aldakheel FM, Rather RA, Afroze D, Rah B. Allemailem KS, et al. Am J Transl Res. 2021 Apr 15;13(4):3868-3889. eCollection 2021. Am J Transl Res. 2021. PMID: 34017579 Free PMC article. Review.
References
- Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–64. - PubMed
- Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bälter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652–658. - PubMed
- Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39:631–637. - PubMed
- Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645–649. - PubMed
- Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39:977–983. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA095052/CA/NCI NIH HHS/United States
- CA105055/CA/NCI NIH HHS/United States
- R01 CA095052-05/CA/NCI NIH HHS/United States
- R01 CA106523-05/CA/NCI NIH HHS/United States
- R01 CA105055/CA/NCI NIH HHS/United States
- CA95052/CA/NCI NIH HHS/United States
- CA106523/CA/NCI NIH HHS/United States
- R01 CA106523/CA/NCI NIH HHS/United States
- R01 CA105055-05/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical